Table 1.
Patient baseline demographics, disease characteristics and treatment dose level.
| No | Age | Histology | ER | PR | Her2 | Prior Therapy a | Sites of Metastatic Disease | Dose Level | |
|---|---|---|---|---|---|---|---|---|---|
| Hormonal (n) | Chemotherapy (n) | ||||||||
| 1 | 58 | Ductal carcinoma | + | − | − | 4 | 2 | Bone, Liver, Lymph nodes, Soft tissue | 1a |
| 2 | 56 | Ductal carcinoma | + | + | − | 5 | 2 | Lymph nodes | 1a |
| 3 | 63 | Lobular carcinoma | + | − | − | 4 | 4 | Bone, Liver | 1a |
| 4 | 47 | Ductal carcinoma | + | + | − | 0 | 7 | Lymph nodes, Soft tissue | 1a |
| 5 | 47 | Ductal carcinoma | + | + | − | 4 | 1 | Bone, Liver, Lung | 2a |
| 6 | 71 | Lobular carcinoma | + | + | unknown | 2 | 0 | Bone | 2a |
| 7 | 55 | Ductal carcinoma | + | + | − | 1 | 0 | Bone | 2a |
| 8 | 73 | Ductal carcinoma | + | + | − | 2 | 0 | Lung, Lymph nodes | Expansion |
a
prior therapies for metastatic disease